IP Library Granted Patent US 12,128,036
Granted Patent B2
US 12,128,036 · App. 18/239,087 · Granted Oct 29, 2024

Compositions and methods for storage stable ophthalmic drugs

Inventor: Gerald Horn (Highland Park, IL)
Assignee: LENZ THERAPEUTICS OPERATIONS, INC.
A61K31/439A61K47/02A61K47/12A61K47/14A61K47/183A61K47/186A61K47/20A61K47/22A61K47/26A61K47/38A61J1/165
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,128,036
App. No.
18/239,087
Granted
Oct 29, 2024
Kind
B2
Abstract

The present invention is related to methods of stabilizing an ophthalmic drug by adding a surfactant and a viscosity enhancer to the ophthalmic drug to create a composition wherein the composition has a viscosity of about 25 centipoise or less at a shear rate of 1/1000 per second at 25 degrees Celsius and a viscosity of about 70 centipoise or more at shear rate of 1 per second at 25 degrees Celsius, filling the composition into a container; and storing the container at a temperature from about 2 degrees Celsius to about 25 degrees Celsius. The present invention is further directed to a container prepared by the methods of the present invention.

Claims (24)

1. A method for treating presbyopia in a subject in need thereof, the method comprising:

(a) providing an aqueous ophthalmological solution comprising aceclidine, wherein the aqueous ophthalmological solution does not comprise a cycloplegic agent;

(b) storing the aqueous ophthalmological solution in a container having a headspace at a temperature from about 2 degrees Celsius to about 8 degrees Celsius for at least 7 months to provide a stored aqueous ophthalmological solution; and

(c) administering the stored aqueous ophthalmological solution to the subject in need thereof, wherein upon administration, the stored aqueous ophthalmological solution comprises at least 90% of the aceclidine that the aqueous ophthalmological solution comprised at the onset of the storing;

thereby treating the presbyopia in the subject.

2. The method of claim 1 , wherein the aqueous ophthalmological solution is stored for at least 12 months.

3. The method of claim 2 , wherein the aqueous ophthalmological solution is stored for at least 18 months.

4. The method of claim 3 , wherein the aqueous ophthalmological solution is stored for at least 24 months.

5. The method of claim 1 , wherein the aqueous ophthalmological solution has a viscosity of about 1 centipoise (cp) to about 25 cps at a high shear of blinking and a viscosity of about 50 cps to about 200 cps at a low shear between blinks.

6. The method of claim 1 , wherein the aqueous ophthalmological solution comprises a pH from about 4.0 to about 8.0.

7. The method of claim 1 , wherein the aceclidine is at a concentration from about 0.25% to about 4.0% w/v aceclidine, wherein w/v denotes weight by total volume of the aqueous ophthalmological solution.

8. The method of claim 7 , wherein the aceclidine is at a concentration from about 0.50% to about 1.90% w/v aceclidine, wherein w/v denotes weight by total volume of the aqueous ophthalmological solution.

9. The method of claim 8 , wherein the aceclidine is at a concentration from about 1.65% to about 1.85% w/v aceclidine, wherein w/v denotes weight by total volume of the aqueous ophthalmological solution.

10. The method of claim 1 , wherein the aqueous ophthalmological solution further comprises a surfactant.

11. The method of claim 1 , wherein the aqueous ophthalmological solution further comprises a viscosity enhancer.

12. The method of claim 11 , wherein the aceclidine remains in the aqueous ophthalmological solution for at least 7 additional months in comparison to an aqueous ophthalmological solution not comprising the viscosity enhancer.

13. The method of claim 1 , wherein the aqueous ophthalmological solution is stored for 7 months to 18 months.

14. The method of claim 1 , wherein the aqueous ophthalmological solution is stored for 7 months.

15. The method of claim 1 , wherein the aqueous ophthalmological solution is stored for about 12 months.

16. The method of claim 1 , wherein the aqueous ophthalmological solution is stored for about 15 months.

17. The method of claim 1 wherein the aqueous ophthalmological solution further comprises a cryoprotectant.

18. The method of claim 1 , wherein the aqueous ophthalmological solution further comprises a polyol.

19. The method of claim 1 , wherein the aqueous ophthalmological solution further comprises mannitol.

20. The method of claim 1 , wherein a cycloplegic agent is not administered to the subject.

Assignments (2)
CHANGE OF NAME Recorded Apr 2, 2024
From: LENZ THERAPEUTICS, INC.
To: LENZ THERAPEUTICS OPERATIONS, INC.
Reel/Frame 066978/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2023
From: HORN, GERALD
To: LENZ THERAPEUTICS, INC.
Reel/Frame 065857/0292 →
Continuity (5)
Continuation 17242398 · Apr 28, 2021
Continuation In Part 17069155 · Oct 13, 2020
Continuation In Part 16595789 · Oct 8, 2019
Provisional Application 62743720 · Oct 10, 2018
Related Publication 20230414587A1 · Dec 28, 2023
Cited By (3)
US 12,414,942 US 12,533,347 US 12,653,779